Energy Balance and Breast Cancer Aspects-II (EBBA-II)
Primary Purpose
DCIS Grade 3, Stage I Breast Cancer, Stage II Breast Cancer
Status
Active
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Intervention. Exercise
Sponsored by
About this trial
This is an interventional prevention trial for DCIS Grade 3
Eligibility Criteria
Inclusion Criteria:
- Age 18-75 years
- Newly diagnosed DCIS grade 3 or invasive breast cancer stage I, II, histologically verified.
- All ethnic groups, but participants have to speak and write the Norwegian language.
- Ability to join and maintain an intervention for 12 months
Exclusion Criteria:
- Verified heart disease
- Dysregulated diabetes mellitus or thyroid disorders
- Muscular and skeletal or other disorders excluding regular physical activity performance
- Body Mass Index >40 kg/m2
- Previous surgical treatment for obesity
- Travel distance >1.5 hour from home to study site
Sites / Locations
- Oslo University Hospital
- St. Olavs Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention. Exercise
Control group
Arm Description
The intervention starts 3-4 weeks after surgical treatment. The exercise program is performed in parallel with standard breast cancer treatment, and take place in supervised exercise groups by experienced physiotherapists. The duration of the intervention exercise program is 12 months, and the participants will attend the exercise groups for training 60 minutes twice a week. Additionally, they will exercise at home for at least 120 minutes a week, aiming to perform a total of 240 minutes of exercise per week
Control group, standard treatment regimen
Outcomes
Primary Outcome Measures
VO2max
Change in VO2max from baseline to 12 months
Secondary Outcome Measures
BMI
Change in BMI from baseline to 12 months
Systolic blood pressure
Change in systolic blood pressure from baseline to 12 months
Diastolic blood pressure
Change in diastolic blood pressure from baseline to 12 months
Total cholesterol
Change in total cholesterol from baseline to 12 months
LDL cholesterol
Change in LDL cholesterol from baseline to 12 months
HDL cholesterol
Change in HDL cholesterol from baseline to 12 months
Total cholesterol/HDL cholesterol
Change in total cholesterol/HDL cholesterol from baseline to 12 months
HbA1c
Change in concentrations of HbA1c from baseline to 12 months
Insulin
Change in concentrations of blood insulin levels (µIU/mL) from baseline to 12 months
Triglycerides
Change in concentrations of triglycerides from baseline to 12 months
C-reactive Protein (CRP)
Change in concentrations of CRP (mg/L) from baseline to 12 months
Heart rate
Change in heart rate from baseline to 12 months
Total fat
Change in total fat from baseline to 12 months
Truncated fat
Change in truncated fat from baseline to 12 months
Waist circumference
Change in waist circumference from baseline to 12 months
Energy from food diary
Change in energy from food diary from baseline to 12 months
Metabolic syndrome
Dichotomous outcome (yes/no)
Full Information
NCT ID
NCT02240836
First Posted
September 5, 2014
Last Updated
April 23, 2021
Sponsor
Oslo University Hospital
Collaborators
St. Olavs Hospital, The Research Council of Norway
1. Study Identification
Unique Protocol Identification Number
NCT02240836
Brief Title
Energy Balance and Breast Cancer Aspects-II
Acronym
EBBA-II
Official Title
Energy Balance and Breast Cancer Aspects-II Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 2014 (Actual)
Primary Completion Date
October 31, 2017 (Actual)
Study Completion Date
October 31, 2027 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital
Collaborators
St. Olavs Hospital, The Research Council of Norway
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study, the EBBA-II trial, is to determine whether a 12 month exercise program comprised of strength and endurance training among newly diagnosed breast cancer patients undergoing adjuvant therapy, will influence cardiopulmonary function. Secondary aims are to determine whether the 12 month exercise program will influence factors associated with metabolic profile, tumor growth, disease-free survival, overall mortality and breast cancer specific mortality. Furthermore, the effect on QoL parameters, and dietary factors will be assessed and evaluated.
Detailed Description
The EBBA (Energy Balance and Breast cancer Aspects)-II study is a randomized clinical 12 month physical activity intervention trial, including female breast cancer patients diagnosed with histologically verified invasive cancer stage I-II or carcinoma in situ (DCIS/LCIS) grade 3.
Participants are randomized to either control or intervention group 10 days +/- 2 days after surgery. The intervention start 3 weeks after surgery and continue throughout adjuvant treatments given (chemotherapy, radiation, endocrine therapy etc). The intervention group receive a detailed training program based on their own ventilatory maximal oxygen consumption (VO2max) at baseline. They meet for supervised training sessions in groups for 60 minutes x 2/ week during 12 months. In addition, they are informed to exercise at home for at least of total 120 minutes weekly aiming to perform a total of 240 minutes exercise, weekly. The patients in the control group receive standard of care without any restrictions regarding exercise.
All participants will undergo a series of measurements before surgery, after surgery, 6 months and after the 12 months exercise intervention trial. Clinical measurements will include anthropometric measurements, fasting blood, fecal and urine samples and cardiopulmonary exercise test (CPET). Complete questionnaires (food diary (PFD)/food frequency questionnaires (FFQ), quality of life (QoL)).
All participants will come to clinical examination and fasting blood sampling after 2, 3, 5 and 10 years follow up.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
DCIS Grade 3, Stage I Breast Cancer, Stage II Breast Cancer, LCIS, Lobular Carcinoma in Situ
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
545 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention. Exercise
Arm Type
Experimental
Arm Description
The intervention starts 3-4 weeks after surgical treatment. The exercise program is performed in parallel with standard breast cancer treatment, and take place in supervised exercise groups by experienced physiotherapists. The duration of the intervention exercise program is 12 months, and the participants will attend the exercise groups for training 60 minutes twice a week. Additionally, they will exercise at home for at least 120 minutes a week, aiming to perform a total of 240 minutes of exercise per week
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Control group, standard treatment regimen
Intervention Type
Other
Intervention Name(s)
Intervention. Exercise
Other Intervention Name(s)
Physical activity
Intervention Description
Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
Primary Outcome Measure Information:
Title
VO2max
Description
Change in VO2max from baseline to 12 months
Time Frame
Baseline,12 months
Secondary Outcome Measure Information:
Title
BMI
Description
Change in BMI from baseline to 12 months
Time Frame
Baseline,12 months
Title
Systolic blood pressure
Description
Change in systolic blood pressure from baseline to 12 months
Time Frame
Baseline,12 months
Title
Diastolic blood pressure
Description
Change in diastolic blood pressure from baseline to 12 months
Time Frame
Baseline,12 months
Title
Total cholesterol
Description
Change in total cholesterol from baseline to 12 months
Time Frame
Baseline,12 months
Title
LDL cholesterol
Description
Change in LDL cholesterol from baseline to 12 months
Time Frame
Baseline,12 months
Title
HDL cholesterol
Description
Change in HDL cholesterol from baseline to 12 months
Time Frame
Baseline,12 months
Title
Total cholesterol/HDL cholesterol
Description
Change in total cholesterol/HDL cholesterol from baseline to 12 months
Time Frame
Baseline,12 months
Title
HbA1c
Description
Change in concentrations of HbA1c from baseline to 12 months
Time Frame
Baseline,12 months
Title
Insulin
Description
Change in concentrations of blood insulin levels (µIU/mL) from baseline to 12 months
Time Frame
Baseline,12 months
Title
Triglycerides
Description
Change in concentrations of triglycerides from baseline to 12 months
Time Frame
Baseline,12 months
Title
C-reactive Protein (CRP)
Description
Change in concentrations of CRP (mg/L) from baseline to 12 months
Time Frame
Baseline,12 months
Title
Heart rate
Description
Change in heart rate from baseline to 12 months
Time Frame
Baseline,12 months
Title
Total fat
Description
Change in total fat from baseline to 12 months
Time Frame
Baseline,12 months
Title
Truncated fat
Description
Change in truncated fat from baseline to 12 months
Time Frame
Baseline,12 months
Title
Waist circumference
Description
Change in waist circumference from baseline to 12 months
Time Frame
Baseline,12 months
Title
Energy from food diary
Description
Change in energy from food diary from baseline to 12 months
Time Frame
Baseline,12 months
Title
Metabolic syndrome
Description
Dichotomous outcome (yes/no)
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
Respiratory Quotient (RQ)
Description
Ratio between the amount of CO2 produced in metabolism and O2 used
Time Frame
12 months
Title
Lactate
Description
Blood lactate from fingertip one minute after test
Time Frame
12 months
Title
HRmax
Description
Maximal heart rate
Time Frame
12 months
Title
BORGmax
Description
Subjective measure of exhaustion
Time Frame
12 months
Title
Disease-free survival
Description
Time from baseline to the date of cancer symptoms or death
Time Frame
Baseline, 1 year, 2 years, 5 years, 10 years
Title
Overall mortality
Description
Time from baseline until the date of death, regardless of the cause of death
Time Frame
Baseline, 1 year, 2 years, 5 years, 10 years
Title
Breast cancer-specific mortality
Description
Time from baseline until the date of breast cancer-specific death
Time Frame
Baseline, 1 year, 2 years, 5 years, 10 years
Title
Other exploratory
Description
Forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), diffusing capacity of the lung for carbon monoxide (DLco)
Inflammatory markers, prothrombotic markers, urinary markers, adipokines
Levels of sex steroid hormones
Growth factors (Insulin-like growth factor [IGF], insulin, insulin-like growth factor binding protein [IGFBP])
Microenvironment of the breast, tumor infiltrating lymphocytes (TILS), Crown like structures (CLS)
Microbiota
Quality of life and dietary factors
Time Frame
12 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18-75 years
Newly diagnosed DCIS grade 3 or invasive breast cancer stage I, II, histologically verified.
All ethnic groups, but participants have to speak and write the Norwegian language.
Ability to join and maintain an intervention for 12 months
Exclusion Criteria:
Verified heart disease
Dysregulated diabetes mellitus or thyroid disorders
Muscular and skeletal or other disorders excluding regular physical activity performance
Body Mass Index >40 kg/m2
Previous surgical treatment for obesity
Travel distance >1.5 hour from home to study site
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Inger Thune, MD. PhD
Organizational Affiliation
The Department of Oncology, Ullevål, Oslo University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oslo University Hospital
City
Oslo
Country
Norway
Facility Name
St. Olavs Hospital
City
Trondheim
ZIP/Postal Code
7000
Country
Norway
12. IPD Sharing Statement
Citations:
PubMed Identifier
9701097
Citation
Thune I, Njolstad I, Lochen ML, Forde OH. Physical activity improves the metabolic risk profiles in men and women: the Tromso Study. Arch Intern Med. 1998 Aug 10-24;158(15):1633-40. doi: 10.1001/archinte.158.15.1633. Erratum In: Arch Intern Med 1998 Jan 11;159(1):17.
Results Reference
background
PubMed Identifier
12525233
Citation
Irwin ML, Yasui Y, Ulrich CM, Bowen D, Rudolph RE, Schwartz RS, Yukawa M, Aiello E, Potter JD, McTiernan A. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: a randomized controlled trial. JAMA. 2003 Jan 15;289(3):323-30. doi: 10.1001/jama.289.3.323.
Results Reference
background
PubMed Identifier
15292387
Citation
Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004 Aug 4;96(15):1152-60. doi: 10.1093/jnci/djh216.
Results Reference
background
PubMed Identifier
14744958
Citation
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004 Jan 27;109(3):433-8. doi: 10.1161/01.CIR.0000111245.75752.C6. No abstract available.
Results Reference
background
PubMed Identifier
24633595
Citation
Courneya KS, Segal RJ, McKenzie DC, Dong H, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Crawford JJ, Mackey JR. Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. Med Sci Sports Exerc. 2014 Sep;46(9):1744-51. doi: 10.1249/MSS.0000000000000297.
Results Reference
background
PubMed Identifier
20159820
Citation
Friedenreich CM, Woolcott CG, McTiernan A, Ballard-Barbash R, Brant RF, Stanczyk FZ, Terry T, Boyd NF, Yaffe MJ, Irwin ML, Jones CA, Yasui Y, Campbell KL, McNeely ML, Karvinen KH, Wang Q, Courneya KS. Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol. 2010 Mar 20;28(9):1458-66. doi: 10.1200/JCO.2009.24.9557. Epub 2010 Feb 16.
Results Reference
background
PubMed Identifier
25144625
Citation
Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Vallerand JR, Adams SC, Proulx C, Dolan LB, Wooding E, Segal RJ. Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy. Br J Cancer. 2014 Oct 28;111(9):1718-25. doi: 10.1038/bjc.2014.466. Epub 2014 Aug 21.
Results Reference
background
PubMed Identifier
24454832
Citation
Edvardsen E, Hem E, Anderssen SA. End criteria for reaching maximal oxygen uptake must be strict and adjusted to sex and age: a cross-sectional study. PLoS One. 2014 Jan 14;9(1):e85276. doi: 10.1371/journal.pone.0085276. eCollection 2014.
Results Reference
background
PubMed Identifier
24419734
Citation
Peel AB, Thomas SM, Dittus K, Jones LW, Lakoski SG. Cardiorespiratory fitness in breast cancer patients: a call for normative values. J Am Heart Assoc. 2014 Jan 13;3(1):e000432. doi: 10.1161/JAHA.113.000432.
Results Reference
background
Learn more about this trial
Energy Balance and Breast Cancer Aspects-II
We'll reach out to this number within 24 hrs